Table 1.
Ref.1 | Study period | Country | Patients | Median follow-up (mo) | Survival | Graft survival |
Terrault et al[2] | 2003-2010 | United States | 89 | 32 | 76% 1 yr | 72% 1 yr |
60% 3 yr | 53% 3 yr | |||||
Miro et al[41] | 2002-2006 | Spain | 84 | 44 | 88% 1 yr | NR |
62% 3 yr | ||||||
54% 5 yr | ||||||
Duclos-Vallée et al[43] | 1999-2005 | France | 35 | 44 | 82% 1 yr | NR |
73% 2 yr | ||||||
51% 5 yr | ||||||
De Vera et al[44] | 1997-2005 | United States | 27 | 27 | 67% 1 yr | 63% 1 yr |
56% 3 yr | 52% 3 yr | |||||
33% 5 yr | 31% 5 yr | |||||
Ragni et al[94] | 1997-2001 | United States | 15 | 17 | 80% 1 yr | NR |
57% 3 yr | ||||||
36% 5 yr | ||||||
Vennarecci et al[95] | 2002-2006 | Italy | 11 | 26 | 83% 1 yr | NR |
58% 3 yr2 | ||||||
Anadol et al[96] | 1997-2011 | Germany | 19 | 613 | 58% 5 yr | NR |
Studies with ≥ 10 patients;
Survival reported for cohort of 12, including one hepatitis B virus/human immunodeficiency virus co-infected patient;
For all patients. NR: Not reported.